FDA Section 361 HCT/P Biologic Procurement Checklist

To ensure regulatory compliance under FDA 21 CFR Part 1271 Section 361, medical practices procuring human cells, tissues, and cellular and tissue-based products (HCT/Ps) must verify that products meet criteria for minimal manipulation, homologous use, and strict current Good Tissue Practice (cGTP) standards. Establishing a structured procurement compliance checklist protects clinical practices from regulatory enforcement while ensuring donor safety, tissue integrity, and seamless chain-of-custody tracking.

Procuring biologics for clinical integration requires balancing therapeutic utility with rigorous regulatory oversight. The Food and Drug Administration (FDA) regulates human cellular and tissue products under two primary pathways: Section 361 and Section 356/351 of the Public Health Service (PHS) Act. For medical practice administrators, office managers, and medical directors, purchasing non-compliant allografts introduces significant operational, financial, and legal vulnerabilities.

Implementing a standardized vendor evaluation and product procurement checklist ensures that every tissue product entering your facility complies with federal law and maintains the highest safety standards.

Understanding FDA Section 361 HCT/P Regulatory Standards

Section 361 HCT/Ps are regulated solely under 21 CFR Part 1271 to prevent the introduction, transmission, or spread of communicable diseases. Unlike Section 351 products—which are classified as biological drugs requiring Pre-Market Approval (PMA) or Biologics License Applications (BLA)—Section 361 tissue products do not require pre-market approval if they fulfill four specific statutory criteria:

1. Minimal Manipulation: Processing does not alter the relevant biological characteristics of the tissue (for structural tissue) or the cellular/relevant biological characteristics (for non-structural tissue).
2. Homologous Use Only: The tissue performs the same basic function or functions in the recipient as in the donor.
3. No Combination with Other Articles: The product is not combined with another drug, device, or systemic agent (except for permissible water, crystalloids, or sterilizing/preserving agents).
4. Metabolic and Systemic Effect Limits: The product either does not rely on the metabolic activity of living cells for its primary function, or it is intended for autologous use, allogeneic use in first- or second-degree relatives, or reproductive use.

Failure to satisfy any one of these four criteria reclassifies the product as a 351 drug, subjecting both the manufacturer and the administering practice to regulatory enforcement if used without an approved BLA or Investigational New Drug (IND) application.

FDA Section 361 HCT/P Procurement Compliance Checklist

Practice managers should execute this checklist for every tissue vendor and biologic product line prior to placing an initial order and review documentation annually.

1. Vendor Registration and Listing

• FDA Establishment Registration: Obtain and verify the vendor’s active FDA Registration and Listing (Form FDA 3356) via the FDA Human Cell and Tissue Establishment Registration Public Query database.
• State Licensing: Confirm the vendor and distributing tissue bank maintain valid state licenses required for tissue distribution in your operating state (e.g., Texas Department of State Health Services tissue bank licensing).
• Annual Renewal: Ensure registration records reflect the current operating year, as FDA establishment registrations expire annually on December 31.

2. Donor Eligibility and Screening (Subpart C)

• Communicable Disease Testing: Verify that donor screening and testing comply with 21 CFR 1271 Subpart C, covering HIV-1/2, Hepatitis B (HBV), Hepatitis C (HCV), Syphilis, and Human T-lymphotropic virus (HTLV) where applicable.
• CLIA-Certified Testing Laboratories: Confirm donor blood specimens were tested by a CLIA-certified laboratory using FDA-licensed donor screening test kits.
• Summary of Records: Require a signed Summary of Records (SOR) with every tissue lot, certifying donor eligibility determination by a licensed Medical Director.

3. Processing and cGTP Adherence (Subpart D)

• Current Good Tissue Practice (cGTP): Obtain documentation demonstrating adherence to 21 CFR 1271 Subpart D guidelines governing facility cleanliness, environmental monitoring, equipment calibration, and process validation.
• Minimal Manipulation Statement: Request written confirmation and processing flowcharts from the manufacturer demonstrating that structural tissue integrity has been preserved without enzymatic digestion or expansion in culture.
• Sterilization Validation: Confirm terminal sterilization methods (such as e-beam or gamma irradiation) or validated aseptic processing protocols with specific Sterility Assurance Levels (SAL).

4. Labeling and Homologous Use Documentation

• Outer Package Labeling: Inspect tissue packaging to ensure standard labeling under 21 CFR 1271.55, including unique donor identifier, product description, expiration date, storage temperature, and instructions for use.
• Intended Use Verification: Confirm the manufacturer’s product insert and promotional literature limit indications strictly to structural, homologous applications.

5. Supply Chain and Storage Logistics

• Chain-of-Custody Tracking: Confirm the distributor uses continuous, validated temperature-monitoring packaging (cryogenic, frozen, or ambient) during transport.
• Receiving Protocols: Audit facility procedures for logging receipt, inspecting outer package integrity, and verifying temperature indicator status upon arrival.

Clinical Perspective: Verifying Homologous Use and Tissue Integrity

For physicians, including pain management specialists and orthopedic specialists, clinical decision-making rests on tissue integrity and regulatory clarity. When procuring allografts such as amnion, cord blood fractions, or fluid derivatives, clinicians must independently confirm that intended administration aligns with structural homologous functions.

Applying a structural allograft to replace, cushion, or support damaged connective tissue is homologous. Conversely, marketing or applying an HCT/P for systemic, anti-inflammatory, or disease-modifying claims moves the product into Section 351 territory. Clinicians should review manufacturer data sheets to ensure clinical rationale matches approved processing parameters, avoiding off-label regulatory exposure while maintaining patient trust.

Operational Perspective: Inventory, Storage, and Risk Management

From a practice administration standpoint, procurement compliance directly impacts practice profitability and operational efficiency. Inventory mismanagement or non-compliant vendor selection creates substantial operational risks:

• Cold-Chain Maintenance: Cryogenic storage equipment (-80°C freezers or liquid nitrogen storage) requires calibrated monitoring systems, backup power solutions, and daily temperature logs to prevent inventory loss.
• Lot Traceability: 21 CFR 1271.290 mandates tissue tracking from the donor source to the recipient or final disposition. Practices must maintain record retention protocols linking the patient medical record to the specific donor lot number for at least 10 years.
• Adverse Event Protocols: Operational policies must define immediate quarantine protocols and vendor notification steps if a tissue contamination or adverse reaction is suspected.

Integrating compliance verification into purchase order workflows prevents buying unapproved biologics, protecting the practice from supply chain disruptions, product recalls, or audit penalties.

What This Means for Your Practice

To translate regulatory requirements into actionable clinical workflow:

1. Audit Existing Biologic Vendors: Immediately request updated FDA Form 3356 records, tissue bank licenses, and Summaries of Records for all current tissue suppliers.
2. Establish Receiving Logs: Implement a standardized physical receiving checklist for incoming biologic shipments, recording lot numbers, expiration dates, and transport temperature compliance.
3. Update Patient Tracking: Verify that your electronic health record (EHR) or tissue inventory management system ties donor lot numbers directly to patient procedure notes.
4. Train Staff on Homologous Claims: Ensure administrative and clinical staff avoid using non-compliant promotional claims regarding biologic products in patient literature or marketing channels.

For additional details on navigating regulatory standards, review our answers to common questions in our FAQ section.

Ensuring Supply Chain Compliance

Securing fully compliant Section 361 HCT/P biologics is essential to safeguarding patient health and maintaining regulatory compliance. Working with experienced distributors who enforce strict screening, temperature logging, and cGTP adherence streamlines your procurement process.

To evaluate your practice’s procurement workflow or review compliant tissue products, contact our team today for a consultation.